Clinical Trials Logo

Positron-Emission Tomography clinical trials

View clinical trials related to Positron-Emission Tomography.

Filter by:

NCT ID: NCT03107663 Completed - Hodgkin Lymphoma Clinical Trials

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

Start date: June 19, 2017
Phase: Phase 1
Study type: Interventional

To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and tumor visualization.

NCT ID: NCT02988531 Completed - Clinical trials for Coronary Artery Disease

Validation of PET-MRI for Cardiovascular Disease

Start date: February 9, 2017
Phase: N/A
Study type: Interventional

To determine whether PET-MRI can obtain comparable images to PET-CT in those with coronary artery disease.

NCT ID: NCT02983318 Completed - Clinical trials for Depressive Disorder, Major

Molecular Imaging of Brain Inflammation in Depressive Disorders

DiME
Start date: August 28, 2017
Phase:
Study type: Observational

In a number of neuropsychiatric disorders such as depression, both brain inflammation and glutamate mediated excitotoxicity (cell death through over-activated stimulation) are suspected to play a key role. It is difficult, if not impossible, to determine the potential destructiveness of the inflammatory response seen in disease states by studying the brain's inflammatory cells (microglia) activity in isolation. The investigators are proposing to develop the means to concurrently study inflammatory response (i.e., microglial activity) and its potentially devastating consequence (i.e., glutamate excitotoxicity) across the entire brain in order to establish the importance of inflammation. In this study the investigators propose a phased clinical study whereby the early-phase involves the development of our capacity to study inflammation-mediated damage to brain cells, followed by a feasibility study in patients with clinical depression that tests whether concurrent inflammation and glutamate excess could be measured in key brain regions associated with a depressed mood state.

NCT ID: NCT02971995 Completed - Prostatic Neoplasm Clinical Trials

Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies

PROSTEPIRM
Start date: December 2014
Phase: N/A
Study type: Interventional

Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection). The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .

NCT ID: NCT01721473 Completed - Clinical trials for Positron Emission Tomography

Brain Nicotine Receptor Density in Veteran Smokers

BNRDVS
Start date: January 1, 2012
Phase:
Study type: Observational

Cigarette smoking is more prevalent among Veterans (27%) than the general U.S. population (21%). Smoking is common among people who use marijuana or caffeine heavily, and the use of menthol cigarettes is becoming increasingly common, affecting approximately 9% of the Veteran population. Recent research by the group and others indicates that heavy marijuana or caffeine use, or the use of predominantly menthol cigarettes, can alter brain nicotinic acetylcholine receptor (nAChR) densities. For the proposed study, brain imaging with PET scanning will be used to determine nicotine receptor densities in Veteran cigarette smokers with and without heavy marijuana or caffeine use, and in menthol and non-menthol Veteran smokers. Results of the proposed research may have implications for improving treatments for Veterans who smoke cigarettes and who have specific drug use co-morbidities or who use menthol cigarettes.

NCT ID: NCT01035164 Completed - Alzheimer's Disease Clinical Trials

Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers

Start date: June 2007
Phase: Phase 1
Study type: Interventional

PET (positron emission tomography) imaging with BAY85-8101 (ZK 6032924) in patients with Alzheimer's Disease compared to healthy volunteers.

NCT ID: NCT01031199 Completed - Multiple Sclerosis Clinical Trials

Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers

Start date: January 2009
Phase: Phase 1
Study type: Interventional

PET (positron emission tomography) imaging with BAY85-8101 for investigation in patients with Multiple Sclerosis compared to healthy volunteers